The Latest Breaking News from UNH

UnitedHealth Group (NYSE:UNH) has reportedly reached a $1 billion agreement to sell its remaining South American operation, Banmedica, to Brazilian private equity firm Patria Investments.

Even though Cigna has lagged behind the broader Nasdaq Composite over the past year, Wall Street analysts remain bullish about the stock’s prospects.

Hedge funds appear to be rebuilding their defensive playbook, and perhaps the clearest tell is a subtle but broad rotation into heavyweight healthcare names. Recent 13F filings show renewed interest in large-cap pharma and managed-care stocks—a shift that could set up a fresh wave of inflows into healthcare ETFs after…

UnitedHealth shares dipped earlier this week as Trump’s populist healthcare remarks rattled insurers, but fundamentals and long-term guidance may tell a more resilient story.

UnitedHealth has considerably underperformed the broader market over the past year, but analysts are cautiously optimistic about the stock’s prospects.

Down almost 50% from all-time highs, UnitedHealth stock trades at a compelling valuation while offering investors an attractive dividend yield.

Despite losing tens of thousands of enrollees in its commercial and Medicaid plans, managed care company UnitedHealth Group Inc. (NYSE:UNH) reported $113 billion in revenue, up 12% year-over-year, and a profit of $4.3 billion during its third quarter results this week.

Defensive blue-chip stock UnitedHealth is on a credible path back to double-digit growth next year, but is UNH a buy right now?

UnitedHealth Group is set up for a robust stock price advance that could add 20% to its stock price relative to late October trading levels.